Just recently, in October 2024, Toader et al. published a case report of a 36-year-old female with prothrombin G20210A mutation-associated thrombophilia, highlighting its potential impact on AVM pathophysiology and management [26]. This evidence concerns the gene F2 and thrombophilia.